Markus Aebi
Corporate Officer/Principal bei Institute of Microbiology
Profil
Dr. Markus Aebi is Chief Scientific Officer at Malcisbo AG and a Professor at Institute of Microbiology.
Dr. Aebi was previously employed as a Principal by Swiss National Science Foundation.
He received his undergraduate degree from the California Institute of Technology and a doctorate degree from the University of Zurich.
Aktive Positionen von Markus Aebi
| Unternehmen | Position | Beginn |
|---|---|---|
| Institute of Microbiology | Corporate Officer/Principal | 22.09.2011 |
Ehemalige bekannte Positionen von Markus Aebi
| Unternehmen | Position | Ende |
|---|---|---|
| Swiss National Science Foundation | Corporate Officer/Principal | 01.01.1994 |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Gründer | - |
Ausbildung von Markus Aebi
| California Institute of Technology | Undergraduate Degree |
| University of Zurich | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| Swiss National Science Foundation | |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
